Article

Memorial Sloan Kettering Ranks First in the Nation for Cancer Care

Author(s):

Memorial Sloan Kettering Cancer Center is proud and honored to announce it has been named the number one hospital for cancer care in the nation.

NEW YORK, NY, July 15, 2014 — Memorial Sloan Kettering Cancer Center is proud and honored to announce it has been named the number one hospital for cancer care in the nation, according to U.S. News & World Report in its annual listing of Best Hospitals. Since the inception of the revered list 25 years ago, MSK has held either the first or second spot each year.

“We are delighted and honored to once again be a top hospital for cancer,” said MSK President and CEO Craig B. Thompson, MD. “But this recognition is really a reflection of an entire community of exceptional people — our dedicated staff of almost 13,000 and our patients, who have placed their trust in our care. We may be number one in the national rankings for this year, but our patients are number one to us every day.”

U.S. News & World Report

The rankings recognize hospitals that excel in treating the most challenging patients. In addition to its ranking for cancer care, MSK was ranked number four for gynecology, number nine for urology, and number 28 for ear, nose, and throat, and was recognized as high performing in the fields of gastroenterology and gastrointestinal surgery and geriatrics. Just 3 percent of the nearly 5,000 hospitals analyzed earned national ranking in even one specialty. Per , hospitals that rank nationally in any specialty have the skill and experience to treat the most complex and demanding cases that can arise in that area. MSK is also ranked among the nation’s top pediatric hospitals.

While competition among medical institutions in the New York metro area is high (MSK ranked number seven of all hospitals in New York City), MSK’s singular focus on cancer means the hospital far outranks its neighbors for cancer care.

U.S. News & World Report

The rankings are determined using a complex set of factors. These include the hospital’s reputation among board-certified physician specialists around the nation, patient survival and safety data, and adequacy of nurse staffing levels, among other criteria. For a complete list and methodology of rankings, please visit U.S. News & World Report.

# # #

About Memorial Sloan Kettering Cancer Center

We are the world’s oldest and largest private cancer center, home to more than 13,000 physicians, scientists, nurses, and staff united by a relentless dedication to conquering cancer. As an independent institution, we combine 130 years of research and clinical leadership with the freedom to provide highly individualized, exceptional care to each patient. And our always-evolving educational programs continue to train new leaders in the field, here and around the world. For more information, go to www.mskcc.org.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
In this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil, discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the need for continued evaluation of prophylactic treatments like tocilizumab (Actemra) and antimicrobial measures for bispecific T-cell engagers, noting logistical and financial challenges and the importance of collaboration with community centers.